zanubrutinib
FDA Grants Accelerated Approval to Brukinsa for Relapsed or Refractory Follicular Lymphoma
The FDA granted accelerated approval to zanubrutinib (Brukinsa, BeiGene) with obinutuzumab (Gazyva, Genentech) for ...
MARCH 8, 2024
New-Generation BTK Inhibitor Found Safer, More Effective for CLL and SLL
Relative to ibrutinib, the second-generation Bruton tyrosine kinase inhibitor zanubrutinib was more effective and ...
JANUARY 16, 2023
Brukinsa Granted Accelerated Approval for Treatment of R/R MZL
The FDA granted accelerated approval to zanubrutinib (Brukinsa, BeiGene) for adults with relapsed or refractory ...
OCTOBER 13, 2021
Load more